AstraZeneca Share Forecast, Price & News

GBX 7,225
-62.00 (-0.85 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: GBX 7,225
50-Day Range
MA: GBX 7,109.88
52-Week Range
Now: GBX 7,225
Volume1.36 million shs
Average Volume2.47 million shs
Market Capitalization£94.85 billion
P/E Ratio29.66
Dividend Yield2.84%
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; and AliveCor, Inc. to develop non-invasive potassium monitoring solutions. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca logo

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Year FoundedN/A



Sales & Book Value

Annual Sales£26.62 billion
Cash FlowGBX 607.89 per share
Book ValueGBX 1,190.10 per share



Outstanding Shares1,312,738,000
Market Cap£94.85 billion
Next Earnings Date4/30/2021 (Estimated)


AstraZeneca (LON:AZN) Given Buy Rating at Shore Capital
April 12, 2021 |  americanbankingnews.com
See More Headlines


Overall MarketRank

1.59 out of 5 stars

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
GBX 7,225
-62.00 (-0.85 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

AstraZeneca (LON:AZN) Frequently Asked Questions

Is AstraZeneca a buy right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 5 sell ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AstraZeneca stock.
View analyst ratings for AstraZeneca
or view top-rated stocks.

What stocks does MarketBeat like better than AstraZeneca?

Wall Street analysts have given AstraZeneca a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AstraZeneca wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Friday, April 30th 2021.
View our earnings forecast for AstraZeneca

How has AstraZeneca's stock price been impacted by COVID-19?

AstraZeneca's stock was trading at GBX 6,955 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AZN stock has increased by 3.9% and is now trading at GBX 7,225.
View which stocks have been most impacted by COVID-19

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Thursday, February 11th. Shareholders of record on Thursday, February 25th will be paid a dividend of GBX 137.40 per share on Monday, March 29th. This represents a dividend yield of 1.87%. The ex-dividend date is Thursday, February 25th. This is an increase from AstraZeneca's previous dividend of GBX 69.60. The official announcement can be viewed at this link.
View AstraZeneca's dividend history

Is AstraZeneca a good dividend stock?

AstraZeneca pays an annual dividend of GBX 2.81 per share and currently has a dividend yield of 2.84%. The dividend payout ratio of AstraZeneca is 1.15%. This payout ratio is at a healthy, sustainable level, below 75%.
View AstraZeneca's dividend history.

What price target have analysts set for AZN?

20 Wall Street analysts have issued twelve-month price targets for AstraZeneca's shares. Their forecasts range from GBX 6,690 to £102. On average, they anticipate AstraZeneca's share price to reach GBX 8,759.44 in the next twelve months. This suggests a possible upside of 21.2% from the stock's current price.
View analysts' price targets for AstraZeneca
or view top-rated stocks among Wall Street analysts.

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot D.V.M., M.B.A., CEO & Exec. Director (Age 62, Pay $4.39M)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 69, Pay $2.45M)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 50)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Exec. VP of HR & Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer
  • Dr. Menelas Pangalos, Exec. Vice-Pres of BioPharmaceuticals R&D
  • Dr. Ruud Dobber, Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
  • Dr. Susan Mary Galbraith, Sr. VP and Head of Research, Early Devel. & Oncology R&D (Age 55)
  • Dr. David B. Goldstein Ph.D., Chief Adviser

Who are some of AstraZeneca's key competitors?

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately GBX 7,225.

How much money does AstraZeneca make?

AstraZeneca has a market capitalization of £94.85 billion and generates £26.62 billion in revenue each year.

How many employees does AstraZeneca have?

AstraZeneca employs 76,100 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

Where are AstraZeneca's headquarters?

AstraZeneca is headquartered at 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.

This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.